Core Viewpoint - The announcement from Hongbo Pharmaceutical indicates that the direct revenue from its DiOrion platform drug development services currently constitutes a small portion of the company's overall revenue, thus not significantly impacting its overall operational performance [1] Group 1 - Since January 8, the company's stock price has increased by more than its peers in the industry and has significantly outperformed related indices such as the ChiNext Index, ChiNext 50, and Shenzhen Component Index [1] - On January 14, Hongbo Pharmaceutical's stock closed up by 16.1%, with a closing price of 65.76 yuan per share [1] - The company warns that the continuous rise in stock price has accumulated considerable profit-taking adjustment risks, urging investors to fully understand secondary market trading risks and to make rational decisions [1]
泓博医药称现阶段DiOrion平台药物研发服务直接收入占整体营业收入的比重较小